Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.57 |
| ▸ | FAAH | O00519 | 7/20 | 0.56 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.54 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.53 |
| ▸ | GPR174 | Q9BXC1 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.47 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16860699 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL29215544 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL8240378 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL25284318 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL29215585 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL25052917 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL29875541 | 1.00 | NOD1 (0.57) | NOD1FAAHASAH1P2RY10GPR174 | |
| Hydrochloric Acid SCHEMBL31297529 | 0.98 | NOD1 (0.56) | NOD1FAAHASAH1P2RY10GPR174 | |
| Hydrochloric Acid SCHEMBL29215303 | 0.98 | NOD1 (0.56) | NOD1FAAHASAH1P2RY10GPR174 | |
| SCHEMBL16860735 | 0.98 | NOD1 (0.55) | NOD1FAAHASAH1P2RY10GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118076582-A | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX生物治疗股份有限公司 | 2024-05-24 | — | — | CN | claimed |
| WO-2024118602-A1 | COMPOSITIONS AND METHODS FOR REDUCING IMMUNE INTOLERANCE AND TREATING AUTOIMMUNE DISORDERS | LAPIX THERAPEUTICS, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| CN-118076582-A | Compositions and methods for reducing immune intolerance and treating autoimmune disorders | LAPIX生物治疗股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| EP-3220961-B1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3087094-B1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | POLYPHOR AG (CH) | 2022-06-01 | — | — | EP | disclosed |
| US-11116816-B2 | Therapeutic vitamin d conjugates | EXTEND BIOSCIENCES, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210008153-A1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES, INC. (US) | 2021-01-14 | — | — | US | disclosed |
| US-10702574-B2 | Therapeutic vitamin D conjugates | EXTEND BIOSCIENCES, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10406202-B2 | Therapeutic vitamin D conjugates | EXTEND BIOSCIENCES, INC. (US) | 2019-09-10 | — | — | US | disclosed |
| US-20190183966-A1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES, INC. (US) | 2019-06-20 | — | — | US | disclosed |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | POLYPHOR AG (CH) | 2019-04-30 | — | — | US | disclosed |
| US-20170216449-A1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-20170216449-A1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES, INC. (US) | 2017-08-03 | — | — | US | disclosed |
| US-9585934-B2 | Therapeutic vitamin D conjugates | EXTEND BIOSCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9585934-B2 | Therapeutic vitamin D conjugates | EXTEND BIOSCIENCES, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160333053-A1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | POLYPHOR AG (CH) | 2016-11-17 | — | — | US | disclosed |
| EP-3087094-A1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | Polyphor AG (CH) | 2016-11-02 | — | — | EP | disclosed |
| US-20160113993-A1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| US-20160113993-A1 | THERAPEUTIC VITAMIN D CONJUGATES | EXTEND BIOSCIENCES, INC. (US) | 2016-04-28 | — | — | US | disclosed |
| WO-2015096873-A1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | POLYPHOR AG (CH) | 2015-07-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333053-A1 | BETA-HAIRPIN PEPTIDOMIMETICS AS SELECTIVE ELASTASE INHIBITORS | SERPINB1, ELANE, XPNPEP1 | NOD1 904/4885FAAH 1020/4885ASAH1 157/4885 |
| US-20210008153-A1 | THERAPEUTIC VITAMIN D CONJUGATES | VDR, CYP24A1, CYP2R1 | NOD1 3756/4885FAAH 1491/4885ASAH1 1179/4885 |
| US-20170216449-A1 | THERAPEUTIC VITAMIN D CONJUGATES | VDR, CYP24A1, CYP2R1 | NOD1 3756/4885FAAH 1491/4885ASAH1 1179/4885 |
| US-10273267-B2 | Beta-hairpin peptidomimetics as selective elastase inhibitors | SERPINB1, ELANE, XPNPEP1 | NOD1 904/4885FAAH 1020/4885ASAH1 157/4885 |
| US-10406202-B2 | Therapeutic vitamin D conjugates | VDR, CYP24A1, PTH1R | NOD1 4264/4885FAAH 1980/4885ASAH1 2640/4885 |
| US-20190183966-A1 | THERAPEUTIC VITAMIN D CONJUGATES | PTH1R, CYP24A1, VDR | NOD1 4007/4885FAAH 1548/4885ASAH1 3034/4885 |
| US-10702574-B2 | Therapeutic vitamin D conjugates | VDR, CYP24A1, CYP2R1 | NOD1 3756/4885FAAH 1491/4885ASAH1 1179/4885 |
| US-20160113993-A1 | THERAPEUTIC VITAMIN D CONJUGATES | VDR, CYP24A1, CYP2R1 | NOD1 3756/4885FAAH 1491/4885ASAH1 1179/4885 |
| US-11116816-B2 | Therapeutic vitamin d conjugates | PTH1R, CYP24A1, VDR | NOD1 4007/4885FAAH 1548/4885ASAH1 3034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.